FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Cotinga Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Cotinga Pharmaceuticals Inc. (COTQF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCOTQF
COTQF
Cotinga Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
COTQF
Home🔹Stocks🔹Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF•OTC

Cotinga Pharmaceuticals Inc.

COTQF•OTC
Market cap
$2.20K
Sentiment

Your view on COTQF

Mkt Cap
$2.20K
Sentiment
Your view
COTQF
Cotinga Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
COTQF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cotinga Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Richard T. Ho
Headquarters
The Canadian Venture Building, Toronto, ON, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Richard T. Ho
Headquarters
The Canadian Venture Building, Toronto, ON, CA
Description

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News